Testosterone

Generic Name
Testosterone
Brand Names
Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo
Drug Type
Small Molecule
Chemical Formula
C19H28O2
CAS Number
58-22-0
Unique Ingredient Identifier
3XMK78S47O
Background

Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication

Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions
Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer
Associated Therapies
-
Clinical Trials
Related News

Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

Phase 3
Completed
Conditions
Advanced Cancer
Interventions
Drug: Testosterone
Drug: Placebo
First Posted Date
2009-08-25
Last Posted Date
2016-09-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
53
Registration Number
NCT00965341
Locations
🇺🇸

The DeBakey VA Medical Center/Baylor College of Medicine, Houston, Texas, United States

🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

First Posted Date
2009-08-20
Last Posted Date
2010-02-11
Lead Sponsor
Repros Therapeutics Inc.
Target Recruit Count
194
Registration Number
NCT00962637
Locations
🇺🇸

Northeast Indiana Research, LLC, Fort Wayne, Indiana, United States

🇺🇸

Salt Lake Research, Salt Lake City, Utah, United States

🇺🇸

Southeastern Research Group, Inc., Tallahassee, Florida, United States

and more 15 locations

Cycled Testosterone Replacement Study

Phase 1
Completed
Conditions
Hypogonadism
Interventions
Drug: Testosterone
Drug: Placebo
First Posted Date
2009-08-12
Last Posted Date
2012-09-10
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
26
Registration Number
NCT00957528
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

Phase 2
Terminated
Conditions
Heart Failure
Interventions
Drug: placebo
Drug: testosterone
First Posted Date
2009-08-12
Last Posted Date
2012-01-13
Lead Sponsor
Warner Chilcott
Target Recruit Count
17
Registration Number
NCT00957034
Locations
🇺🇸

Research Site, Tacoma, Washington, United States

Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men

Phase 1
Completed
Conditions
Contraception
Interventions
Drug: Testosterone
Drug: Nestorone®
First Posted Date
2009-05-01
Last Posted Date
2018-05-24
Lead Sponsor
Health Decisions
Target Recruit Count
99
Registration Number
NCT00891228
Locations
🇺🇸

Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California, United States

🇺🇸

University of Washington, Seattle, Washington, United States

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

First Posted Date
2008-12-09
Last Posted Date
2018-08-01
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
61
Registration Number
NCT00805207
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: testosterone
First Posted Date
2008-11-17
Last Posted Date
2013-04-17
Lead Sponsor
Warner Chilcott
Target Recruit Count
110
Registration Number
NCT00791856
Locations
🇺🇸

Antonio Pizarro, MD, Fort Myers, Florida, United States

🇺🇸

David R Mathews, MD, Overland Park, Kansas, United States

🇺🇸

Maria J Gulierrez, MD, Miramar, Florida, United States

and more 1 locations

Influence of Administration Route of Testosterone on Male Fertility

Phase 1
Withdrawn
Conditions
Hypogonadism
Interventions
Drug: MPP10, testosterone
Drug: Testosterone
First Posted Date
2008-06-26
Last Posted Date
2018-03-13
Lead Sponsor
Acerus Pharmaceuticals Corporation
Registration Number
NCT00705796
Locations
🇳🇱

AMPHA, Nijmegen, Netherlands

Metabolic Effects of Androgenicity in Aging Men and Women

Not Applicable
Completed
Conditions
Aging
Insulin Resistance
Interventions
Drug: Testosterone
Drug: Estrogen
First Posted Date
2008-05-20
Last Posted Date
2017-06-15
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
33
Registration Number
NCT00680797
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States

Effects of Testosterone in Women With Depression

Not Applicable
Completed
Conditions
Depression
Interventions
Drug: Testosterone
First Posted Date
2008-05-13
Last Posted Date
2012-11-30
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
9
Registration Number
NCT00676676
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy